Sökning: onr:"swepub:oai:DiVA.org:uu-485849" >
Cost of healthcare ...
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes : A multinational, observational study across 12 countries
-
- Norhammar, Anna (författare)
- Karolinska Institutet
-
- Bodegard, Johan (författare)
- AstraZeneca, Oslo, Norway.
-
- Eriksson, Jan W. (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
visa fler...
-
- Haller, Hermann (författare)
- Hannover Med Sch, Div Nephrol, Hannover, Germany.
-
- Linssen, Gerard C. M. (författare)
- Hosp Grp Twente, Dept Cardiol, Almelo, Netherlands.;Hosp Grp Twente, Dept Cardiol, Hengelo, Netherlands.
-
- Banerjee, Amitava (författare)
- UCL, Inst Hlth Informat, London, England.;Univ Coll London Hosp, Dept Cardiol, London, England.
-
- Karasik, Avraham (författare)
- Maccabi Healthcare Serv, Maccabi Inst Res & Innovat, Tel Aviv, Israel.
-
- Mamouris, Pavlos (författare)
- Katholieke Univ Leuven, Acad Ctr Gen Practice, Leuven, Belgium.
-
- Tangri, Navdeep (författare)
- Univ Manitoba, Dept Med & Community Hlth Sci, Winnipeg, MB, Canada.
-
- Taveira-Gomes, Tiago (författare)
- Univ Porto, Fac Med, Dept Community Med Informat & Decis Hlth, Porto, Portugal.
-
- Maggioni, Aldo P. (författare)
- ANMCO Res Ctr, Florence, Italy.;Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy.
-
- Botana, Manuel (författare)
- Lucus Augusti Univ Hosp, Endocrinol Serv, Lugo, Spain.
-
- Thuresson, Marcus (författare)
- Statisticon AB, Uppsala, Sweden.
-
- Okami, Suguru (författare)
- AstraZeneca, Osaka, Japan.
-
- Yajima, Toshitaka (författare)
- AstraZeneca, Osaka, Japan.
-
- Kadowaki, Takashi (författare)
- Tranomon Hosp, Tokyo, Japan.
-
- Birkeland, Kåre I. (författare)
- Oslo Univ Hosp, Dept Transplantat Med, Oslo, Norway.;Univ Oslo, Oslo, Norway.
-
visa färre...
-
Karolinska Institutet AstraZeneca, Oslo, Norway (creator_code:org_t)
- 2022-04-19
- 2022
- Engelska.
-
Ingår i: Diabetes, obesity and metabolism. - : John Wiley & Sons. - 1462-8902 .- 1463-1326. ; 24:7, s. 1277-1287
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- AimTo examine how the development of cardiovascular and renal disease (CVRD) translates to hospital healthcare costs in individuals with type 2 diabetes (T2D) initially free from CVRD.MethodsData were obtained from the digital healthcare systems of 12 nations using a prespecified protocol. A fixed country-specific index date of 1 January was chosen to secure sufficient cohort disease history and maximal follow-up, varying between each nation from 2006 to 2017. At index, all individuals were free from any diagnoses of CVRD (including heart failure [HF], chronic kidney disease [CKD], coronary ischaemic disease, stroke, myocardial infarction [MI], or peripheral artery disease [PAD]). Outcomes during follow-up were hospital visits for CKD, HF, MI, stroke, and PAD. Hospital healthcare costs obtained from six countries, representing 68% of the total study population, were cumulatively summarized for CVRD events occurring during follow-up.ResultsIn total, 1.2 million CVRD-free individuals with T2D were identified and followed for 4.5 years (mean), that is, 4.9 million patient-years. The proportion of individuals indexed before 2010 was 18% (n = 207 137); 2010-2015, 31% (361 175); and after 2015, 52% (609 095). Overall, 184 420 (15.7%) developed CVRD, of which cardiorenal disease was most frequently the first disease to develop (59.7%), consisting of 23.0% HF and 36.7% CKD, and more common than stroke (16.9%), MI (13.7%), and PAD (9.7%). The total cumulative cost for CVRD was US$1 billion, of which 59.0% was attributed to cardiorenal disease, 3-, 5-, and 6-fold times greater than the costs for stroke, MI, and PAD, respectively.ConclusionAcross all nations, HF or CKD was the most frequent CVRD manifestation to develop in a low-risk population with T2D, accounting for the highest proportion of hospital healthcare costs. These novel findings highlight the importance of cardiorenal awareness when planning healthcare.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- cardiovascular disease
- diabetic nephropathy
- health economics
- heart failure
- SGLT2 inhibitor
- type 2 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Norhammar, Anna
-
Bodegard, Johan
-
Eriksson, Jan W.
-
Haller, Hermann
-
Linssen, Gerard ...
-
Banerjee, Amitav ...
-
visa fler...
-
Karasik, Avraham
-
Mamouris, Pavlos
-
Tangri, Navdeep
-
Taveira-Gomes, T ...
-
Maggioni, Aldo P ...
-
Botana, Manuel
-
Thuresson, Marcu ...
-
Okami, Suguru
-
Yajima, Toshitak ...
-
Kadowaki, Takash ...
-
Birkeland, Kåre ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes, obesit ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet